87,845 Shares in Edgewise Therapeutics, Inc. $EWTX Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 87,845 shares of the company’s stock, valued at approximately $3,567,000. Lisanti Capital Growth LLC owned 0.08% of Edgewise Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Hsbc Holdings PLC purchased a new stake in Edgewise Therapeutics during the second quarter worth $3,723,000. Janus Henderson Group PLC increased its holdings in shares of Edgewise Therapeutics by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock valued at $186,289,000 after acquiring an additional 1,348,706 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Edgewise Therapeutics in the 2nd quarter valued at $2,821,000. The Manufacturers Life Insurance Company purchased a new position in shares of Edgewise Therapeutics in the 2nd quarter valued at $1,656,000. Finally, California State Teachers Retirement System raised its position in shares of Edgewise Therapeutics by 45.7% in the 1st quarter. California State Teachers Retirement System now owns 73,419 shares of the company’s stock worth $2,313,000 after acquiring an additional 23,027 shares in the last quarter.

Edgewise Therapeutics Stock Up 2.2%

Shares of EWTX opened at $47.57 on Thursday. The company has a 50 day moving average of $41.18 and a two-hundred day moving average of $36.81. Edgewise Therapeutics, Inc. has a twelve month low of $19.76 and a twelve month high of $48.78. The company has a market cap of $5.21 billion, a price-to-earnings ratio of 5.81 and a beta of 0.39.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $9.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $10.18. On average, sell-side analysts expect that Edgewise Therapeutics, Inc. will post 6.92 EPS for the current year.

Analyst Ratings Changes

EWTX has been the subject of a number of analyst reports. Raymond James Financial restated an “underperform” rating and set a $85.00 price objective on shares of Edgewise Therapeutics in a research note on Thursday, November 5th. The Goldman Sachs Group raised their price objective on Edgewise Therapeutics from $32.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. William Blair assumed coverage on Edgewise Therapeutics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Evercore reiterated an “outperform” rating and issued a $55.00 target price on shares of Edgewise Therapeutics in a report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Thursday, October 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Edgewise Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $52.83.

Insiders Place Their Bets

In related news, CFO Michael Nofi sold 4,442 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $45.43, for a total transaction of $201,800.06. Following the transaction, the chief financial officer directly owned 6,495 shares of the company’s stock, valued at $295,067.85. This represents a 40.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 21.30% of the stock is currently owned by company insiders.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.